Table 2.

Ongoing clinical trials with domestic PD-1 or PD-L1 inhibitors on advanced tumors and NSCLC

Drugs and indentifier	The role of China	Phase	Indication	Design	State	Enrollment
SHR-1210 CTR20160175	Sponsor	I	Advanced solid tumors	Non-randomized, open-label, single-center, dose-escalation	Recruiting	45
SHR-1210 CTR20170090	Sponsor	II S + A	Advanced NSCLC	Non-randomized, open-label, single-center, dose-escalation	Recruiting	118
SHR-1210 CTR20170299	Sponsor	II	Advanced NSCLC	Open-label, single-arm, multicenter	Not yet recruiting	120
SHR-1210 CTR20170322	Sponsor	III S + P + C	Advanced non-squamous NSCLC	Randomized, open-label, multicenter	Not yet recruiting	412
JS-001 CTR20160274	Sponsor	I	Advanced solid tumors	Open-label, single-group assignment	Recruiting	54
IBI308 CTR20160735	Sponsor	I	Advanced malignant tumors	Non-randomized, open-label, single-group assignment	Recruiting	104
BGB-A317 CTR20160872	Sponsor	I	Advanced solid tumors	Non-randomized, open-label, single-group assignment	Not yet recruiting	300

NSCLC non-small cell lung cancer, S + A SHR-1211 plus apatinib, S + P + C SHR-1210 plus pemetrexed and carboplatin